Skip to content
EntityQ76797798· pop 10· linked from 60 articles

Also known as (3S)-N-[(3S,5S,6R)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1H-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide, AGN-241689, MK-8031, Qulipta

Atogepant, sold under the brand name Qulipta among others, is a medication used to prevent migraines. It is a gepant, a calcitonin gene-related peptide receptor antagonist administered orally.

Key facts

Drug.image
Atogepant.svg
Drug.image_class
skin-invert-image
Drug.tradename
Qulipta, Aquipta
Drug.MedlinePlus
a621052
Drug.DailyMedID
Atogepant
Drug.pregnancy_AU
B3
Drug.routes_of_administration
By mouth
Drug.ATC_prefix
N02
Drug.ATC_suffix
CD07
Drug.legal_AU
S4
Drug.legal_CA
Rx-only
Drug.legal_US
Rx-only
Drug.legal_EU
Rx-only
Drug.CAS_number
1374248-81-3
Drug.PubChem
72163100
Drug.DrugBank
DB16098
Drug.ChemSpiderID
59718640
Drug.UNII
7CRV8RR151

via Wikipedia infobox

~3 min read

Encyclopedic overview

4 sections
Contents
  • Medical uses
  • History
  • Research
  • References

Atogepant, sold under the brand name Qulipta among others, is a medication used to prevent migraines. It is a gepant, a calcitonin gene-related peptide receptor antagonist administered orally.

The most common side effects include nausea, constipation, tiredness, somnolence (sleepiness), decreased appetite, and decreased weight.

Excerpted from Wikipedia’s “atogepant” article, available under the CC BY-SA 4.0 licence.

Available in 10 languages

via Wikidata sitelinks · CC0